1474024-65-1

Basic information

• Product Name: (R)-((R)-2-(2,4-difluorophenyl)oxiran-2-yl)(5-fluoropyrimidin-4-yl)methanol
• Synonyms: (R)-((R)-2-(2,4-difluorophenyl)oxiran-2-yl)(5-fluoropyrimidin-4-yl)methanol
• CAS NO: 1474024-65-1
• Molecular Weight: 282.222
• Mol File: 1474024-65-1.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 400.1±45.0 °C(Predicted)
• Density: 1.546±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (R)-((R)-2-(2,4-difluorophenyl)oxiran-2-yl)(5-fluoropyrimidin-4-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-((R)-2-(2,4-difluorophenyl)oxiran-2-yl)(5-fluoropyrimidin-4-yl)methanol(1474024-65-1)
• EPA Substance Registry System: (R)-((R)-2-(2,4-difluorophenyl)oxiran-2-yl)(5-fluoropyrimidin-4-yl)methanol(1474024-65-1)

Safety Data

• Hazardous Substances Data: 1474024-65-1(Hazardous Substances Data)

Usage

Description

(R)-((R)-2-(2,4-difluorophenyl)oxiran-2-yl)(5-fluoropyrimidin-4-yl)methanol, commonly known as Dabrafenib, is a targeted cancer medication that selectively inhibits the activity of a mutated protein involved in the growth and spread of cancer cells. (R)-((R)-2-(2,4-difluorophenyl)oxiran-2-yl)(5-fluoropyrimidin-4-yl)methanol is characterized by its ability to specifically target cancer cells, resulting in fewer side effects on normal cells. Dabrafenib is typically used in combination with other medications to enhance its therapeutic effects.

Uses

Used in Oncology:
Dabrafenib is used as an anticancer agent for the treatment of melanoma with BRAF V600E or V600K mutations. It functions by blocking the action of the mutated protein, thereby inhibiting cancer cell growth and spread. This targeted therapy approach minimizes side effects on healthy cells and is often used in combination with other medications, such as trametinib, to improve treatment outcomes.
Common side effects associated with Dabrafenib use include fever, fatigue, nausea, and skin rashes. It is crucial to consult a healthcare professional before using Dabrafenib, as it may interact with other medications or be contraindicated in certain medical conditions.

Upstream product

• 1003706-87-3 4-bromo-5-fluoro-pyrimidine 
• 861718-85-6 3-chloro-2-(2,4-difluorophenyl)-2-(trimethylsilanyloxy)propionaldehyde 

Downstream Products

• 1474024-67-3 (R)-4-(1-(2-(2,4-difluorophenyl)oxirane-2-yl)vinyl)-5-fluoropyrimidine 
• 1474024-68-4 4-((S)-1-((R)-2-(2,4-difluorophenyl)oxirane-2-yl)ethyl)-5-fluoropyrimidine 
• 1547229-02-6 4-((R)-1-((R)-2-(2,4-difluorophenyl)oxiran-2-yl)ethyl)-5-fluoropyrimidine 
• 137234-63-0 (2S,3R)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol 
• 137234-62-9 voriconazole 
• 1474024-70-8 (E)-2-(2,4-difluorophenyl)-1-(5-fluoropyrimidin-4-yl)-3-hydroxyprop-1-en-1-yl methanesulfonate 
• 1474024-71-9 (E)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)but-2-en-1-ol 
• 1474024-78-6 (Z)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)but-2-en-1-ol 
• 1474024-75-3 7-(2,4-difluorophenyl)-8-methyl-6H-pyrano[3,2-d]pyrimidine 
• 1474024-72-0 (E)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-4-(1H-1,2,4-triazol-1-yl)but-2-en-1-ol 
• 1474024-73-1 8-((1H-1,2,4-triazol-1-yl)-methyl)-7-(2,4-difluorophenyl)-6H-pyrano[3,2-d]pyrimidine 
• 1474024-74-2 (R)-(5-(1H-1,2,4-triazol-1-yl)pyrimidin-4-yl)(2-(2, 4-difluorophenyl)oxiran-2-yl)methanone 
• 1474024-76-4 (3R)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-2-(4H-1,2,4-triazol-4-yl)butan-1-ol 
• 1474024-69-5 (R)-((R)-2-(2,4-difluorophenyl)oxiran-2-yl)(5-fluoropyrimidin-4-yl)methyl methanesulfonate 

Relevant articles and documents

COMPOUND AND METHOD FOR MANUFACTURING THE SAME, AND METHOD FOR MANUFACTURING VORICONAZOLE

PROBLEM TO BE SOLVED: To provide a method for manufacturing voriconazole, which is a therapeutic agent for severe or intractable deep mycosis such as aspergillosis, allowing easy manufacture without the need for the optical resolution. SOLUTION: A method for manufacturing voriconazole includes: obtaining a compound represented by the general formula (3) by using catalytic asymmetric cyanoacylation reaction; and reacting the compound with 1,2,4-triazole to convert it into voriconazole. [In the general formula (3), X is any of the divalent groups represented by the specified structural formulas.] COPYRIGHT: (C)2015,JPOandINPIT